⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2024Diabetes Technology & Therapeutics

Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience

Bella Halim Mary B. Abraham Georgina Manos Arcelia Arrieta Zheng Dai Sara Vogrin Jean Lu Richard J. MacIsaac Elif I. Ekinci Elizabeth A. Davis Alicia J. Jenkins John Shin Robert A. Vigersky Timothy W. Jones David N. O’Neal

View at Publisher

Ask AI

Bookmark

Share

Abstract

To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Halim et al. (2024) studied this question.

synapsesocial.com/papers/68e761d7b6db6435876d8487 https://doi.org/10.1089/dia.2023.0348

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitusOriginal Research · 2022 · 32 citations
2Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems2024 · 19 citations
3Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in GreeceRetrospective Study · 2026
41863-P: Medicare Beneficiaries with Type 1 and Type 2 Diabetes Using the MiniMed 780G System Exceed Glycemic TargetsOriginal Research · 2026
5Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States2024 · 27 citations

More related papers

Impact of minimed780G insulin pump therapy on quality of life in children and adolescents with type 1 diabetes: A comparative analysis2025
Long-Term Cost-Effectiveness of an Advanced Hybrid Closed-Loop Automated Insulin Delivery System Versus Multiple Daily Insulin Injections Plus Continuous Glucose Monitoring in Adults with Type 1 Diabetes in Australia2026
Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain2026

More from Diabetes Technology & Therapeutics

Continuous Glucose Monitoring Is Not Ready for the Diagnosis of PrediabetesMon,
Real-World Clinical Outcomes Following Initiation of the iLet® Bionic Pancreas in Youth with Type 1 DiabetesWed,